Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical...
29 insider purchases on record · latest filing 2025-06-20.
Insiders have also filed 5 sale transactions at IMUX.